Modulation of vitamin D signaling is a potential therapeutic target to lower cardiovascular risk in chronic kidney disease

Medical Science Monitor

Volumn 17, Issue 6, 2011, Pages

  Hu, Peng ^a   Hu, Bo ^a   Wang, Jing ^a   Lu, Ling ^a   Qin, Yuan Han ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Chronic kidney disease; Endothelial function; Thrombosis; Vitamin D

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; ANGIOTENSIN; C REACTIVE PROTEIN; CALCIUM PHOSPHATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RENIN; TRIACYLGLYCEROL; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HOMEOSTASIS; HUMAN; HYPERPARATHYROIDISM; INFLAMMATION; KIDNEY FAILURE; LIPID METABOLISM; METABOLISM; MODULATION; MORTALITY; OUTCOME ASSESSMENT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SUN EXPOSURE; THROMBOSIS; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 79958756114     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881790     Document Type: Review

References (107)

1. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol, 1998; 9(1,2 Suppl.): S16-23
2. Oh J, Wunsch R, Turzer M et al: Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation, 2002; 106(1): 100-5
3. Mann JF, Gerstein HC, Dulau-Florea I et al: Cardiovascular risk in patients with mild renal insufficiency. Kidney Int Suppl, 2003; (84): S192-96
4. Groothoff JW, Lilien MR, van de Kar NC et al: Cardiovascular disease as a late complication of end-stage renal disease in children. Pediatr Nephrol, 2005; 20(3): 374-79
5. McMahon LP: Hemodynamic cardiovascular risk factors in chronic kidney disease: what are the effects of intervention? Semin Dial, 2003; 16(2): 128-39
6. Tsimihodimos V, Dounousi E, Siamopoulos KC: Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol, 2008; 28(6): 958-73
7. Crutchlow MF, Robinson B, Pappachen B et al: Validation of steadystate insulin sensitivity indices in chronic kidney disease. Diabetes Care, 2007; 30(7): 1813-18
8. Fried L, Solomon C, Shlipak M et al: Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol, 2004; 15(12): 3184-91
9. Kielstein JT, Salpeter SR, Buckley NS et al: Two cardiovascular risk factors in one? Homocysteine and its relation to glomerular filtration rate. A meta-analysis of 41 studies with 27,000 participants. Kidney Blood Press Res, 2008; 31(4): 259-67
10. Oberg BP, McMenamin E, Lucas FL et al: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int, 2004; 65(3): 1009-16
11. Desir GV: Renalase is a novel renal hormone that regulates cardiovascular function. J Am Soc Hypertens, 2007; 1(2): 99-103
12. Menon V, Greene T, Pereira AA et al: Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis, 2005; 46(3): 455-63
13. Rakhit DJ, Marwick TH, Armstrong KA et al: Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart, 2006; 92(10): 1402-8
14. Kaisar MO, Isbel NM, Johnson DW: Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease. Rev Recent Clin Trials, 2008; 3(2): 79-88
15. Beale MG, Chan JC, Oldham SB et al: Vitamin D: the discovery of its metabolites and their therapeutic applications. Pediatrics, 1976; 57(5): 729-41
16. Stamp TC: Vitamin D metabolism. Recent advances. Arch Dis Child, 1973; 48(1): 2-7
17. Haussler MR, Haussler CA, Jurutka PW et al: The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol, 1997; 154(Suppl): S57-73
18. Amizuka N, Kwan MY, Goltzman D et al: Vitamin D3 differentially regulates parathyroid hormone/parathyroid hormone-related peptide receptor expression in bone and cartilage. J Clin Invest, 1999; 103(3): 373-81
19. Sypniewska G, Sobanska I, Pater A et al: Does serum osteoprotegerin level relate to fragility fracture in elderly women with low vitamin D status? Med Sci Monit, 2010; 16(2): CR96-101
20. Holick MF: Vitamin D and sunlight: strategies for cancer prevention and other health benefits. Clin J Am Soc Nephrol, 2008; 3(5): 1548-54
21. Judd SE, Tangpricha V: Vitamin D deficiency and risk for cardiovascular disease. Am J Med Sci, 2009; 338(1): 40-44
22. Grimes DS, Hindle E, Dyer T: Sunlight, cholesterol and coronary heart disease. QJM, 1996; 89(8): 579-89
23. Douglas AS, Dunnigan MG, Allan TM et al: Seasonal variation in coronary heart disease in Scotland. J Epidemiol Community Health, 1995; 49(6): 575-82
24. Rostand SG: Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension, 1997; 30(2 Pt 1): 150-56
25. Giovannucci E, Liu Y, Hollis BW et al: 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med, 2008; 168(11): 1174-80
26. Artaza JN, Mehrotra R, Norris KC: Vitamin D and the cardiovascular system. Clin J Am Soc Nephrol, 2009; 4(9): 1515-22
27. Pfeifer M, Begerow B, Minne HW et al: Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab, 2001; 86(4): 1633-37
28. Barreto DV, Barreto FC, Liabeuf S et al: Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol, 2009; 4(6): 1128-35
29. London GM, Guérin AP, Verbeke FH et al: Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol, 2007; 18(2): 613-20
30. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis, 2003; 42(4 Suppl.3): S1-201
31. Williams S, Malatesta K, Norris K: Vitamin D and chronic kidney disease. Ethn Dis, 2009; 19(4 Suppl.5): S5-8-11
32. Somjen D, Weisman Y, Kohen F et al: 25-hydroxyvitamin D3-1alphahydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation, 2005; 111(13): 1666-71
33. Hewison M, Burke F, Evans KN et al: Extra-renal 25-hydroxyvitamin D3- 1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol, 2007; 103(3-5): 316-21
34. Hur SJ, Kim DM, Lim KH et al: Vitamin D levels and their relationship with cardiac biomarkers in chronic hemodialysis patients. J Korean Med Sci, 2009; 24(Suppl.1): S109-14
35. Covic A, Voroneanu L, Goldsmith D: The Effects of Vitamin D Therapy on Left Ventricular Structure and Function - Are These the Underlying Explanations for Improved CKD Patient Survival? Nephron Clin Pract, 2010; 116(3): c187-95
36. Baksi SN, Hughes MJ: Deficiency in dietary vitamin D, not calcium, alters noradrenergic responsiveness in rat atria in vitro. J Mol Cell Cardiol, 1986; 18(7): 653-56
37. Weishaar RE, Kim SN, Saunders DE et al: Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol, 1990; 258(1 Pt 1): E134-42
38. Watson KE, Abrolat ML, Malone LL et al: Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation, 1997; 96(6): 1755-60
39. Milliner DS, Zinsmeister AR, Lieberman E et al: Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int, 1990; 38(5): 931-36
40. Goldsmith DJ, Covic A, Sambrook PA et al: Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron, 1997; 77(1): 37-43
41. Kingma JG Jr, Roy PE: Ultrastructural study of hypervitaminosis D induced arterial calcification in Wistar rats. Artery, 1988; 16(1): 51-61
42. Mathew S, Lund RJ, Chaudhary LR et al: Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol, 2008; 19(8): 1509-19
43. Kunitomo M, Kinoshita K, Bandô Y: Experimental atherosclerosis in rats fed a vitamin D, cholesterol-rich diet. J Pharmacobiodyn, 1981; 4(9): 718-23
44. Zisman AL, Wolf M: Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. Curr Opin Nephrol Hypertens, 2010; 19(4): 335-42
45. Mirza MA, Larsson A, Lind L et al: Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis, 2009; 205(2): 385-90
46. Ix JH, Shlipak MG, Wassel CL et al: Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant, 2010; 25(3): 993-97
47. Shimada T, Urakawa I, Isakova T et al: Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab, 2010; 95(2): 578-85
48. Reis JP, Michos ED, von Mühlen D et al: Differences in vitamin D status as a possible contributor to the racial disparity in peripheral arterial disease. Am J Clin Nutr, 2008; 88(6): 1469-77
49. Cozzolino M, Malindretos P: The role of vitamin D receptor activation in chronic kidney disease. Hippokratia, 2010; 14(1): 7-9
50. Malluche HH, Monier-Faugere MC, Koszewski NJ: Use and indication of vitamin D and vitamin D analogues in patients with renal bone disease. Nephrol Dial Transplant, 2002; 17(Suppl.10): 6-9
51. Hagström E, Hellman P, Larsson TE et al: Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation, 2009; 119(21): 2765-71
52. Coen G, Mantella D, Sardella D et al: Asymmetric dimethylarginine, vascular calcifications and parathyroid hormone serum levels in hemodialysis patients. J Nephrol, 2009; 22(5): 616-22
53. Song GJ, Fiaschi-Taesch N, Bisello A: Endogenous parathyroid hormone- related protein regulates the expression of PTH type 1 receptor and proliferation of vascular smooth muscle cells. Mol Endocrinol, 2009; 23(10): 1681-90
54. Cha H, Jeong HJ, Jang SP et al: Parathyroid hormone accelerates decompensation following left ventricular hypertrophy. Exp Mol Med, 2010; 42(1): 61-68
55. di Leo C, Gallieni M, Bestetti A et al: Cardiac and pulmonary calcification in a hemodialysis patient: partial regression 4 years after parathyroidectomy. Clin Nephrol, 2003; 59(1): 59-63
56. Amann K, Ritz E, Wiest G et al: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol, 1994; 4(10): 1814-19
57. Nishizawa Y, Miki T, Okui Y et al: Deranged metabolism of lipids in patients with chronic renal failure: possible role of secondary hyperparathyroidism. Jpn J Med, 1986; 25(1): 40-45
58. Ogard CG, Engelmann MD, Kistorp C et al: Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf), 2005; 63(5): 493-98
59. De Boer IH, Gorodetskaya I, Young B et al: The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol, 2002; 13(11): 2762-69
60. Walker MD, Fleischer JB, di Tullio MR et al: Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab, 2010; 95(5): 2172-79
61. Tripepi G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol, 2005; 16(Suppl.1): S83-88
62. Galle J, Quaschning T, Seibold S et al: Endothelial dysfunction and inflammation: what is the link? Kidney Int Suppl, 2003; (84): S45-49
63. Mackiewicz A, Speroff T, Ganapathi MK et al: Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol, 1991; 146(9): 3032-37
64. Fantuzzi G, Zheng H, Faggioni R et al: Effect of endotoxin in IL-1 beta- deficient mice. J Immunol, 1996; 157(1): 291-96
65. Marino MW, Dunn A, Grail D et al: Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA, 1997; 94(15): 8093-98
66. Fiscella K, Franks P: Vitamin D, race, and cardiovascular mortality: findings from a national US sample. Ann Fam Med, 2010; 8(1): 11-18
67. Silvestro A, Scopacasa F, Ruocco A et al: Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease. Vasc Med, 2003; 8(4): 225-32
68. Guijarro C, Egido J: Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int, 2001; 59(2): 415-24
69. Wu-Wong JR, Nakane M, Ma J et al: Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis, 2006; 186(1): 20-28
70. Hu P, Qin YH, Pei J et al: Beneficial effect of all-trans retinoic acid (ATRA) on glomerulosclerosis rats via the down-regulation of the expression of alpha-smooth muscle actin: a comparative study between ATRA and benazepril. Exp Mol Pathol, 2010; 89(1): 51-57
71. Renke M, Tylicki L, Rutkowski P et al: The effect of N-acetylcysteine on blood pressure and markers of cardiovascular risk in non-diabetic patients with chronic kidney disease: a placebo-controlled, randomized, cross-over study. Med Sci Monit, 2010; 16(7): PI13-18
72. Li YC, Kong J, Wei M et al: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest, 2002; 110(2): 229-38
73. Wang AY, Lam CW, Sanderson JE et al: Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr, 2008; 87(6): 1631-38
74. Yuan W, Pan W, Kong J et al: 1,25-dihydroxyvitamin D3 suppresses rennin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem, 2007; 282(41): 29821-30
75. Wang TJ, Pencina MJ, Booth SL et al: Vitamin D deficiency and risk of cardiovascular disease. Circulation, 2008; 117(4): 503-11
76. Chonchol M, Cigolini M, Targher G: Association between 25-hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic patients with mild kidney dysfunction. Nephrol Dial Transplant, 2008; 23(1): 269-74
77. Petchey WG, Hickman IJ, Duncan E et al: The role of 25-hydroxyvitamin D deficiency in promoting insulin resistance and inflammation in patients with chronic kidney disease a randomised controlled trial. BMC Nephrol, 2009; 10: 41
78. de Boer IH: Vitamin D and glucose metabolism in chronic kidney disease. Curr Opin Nephrol Hypertens, 2008; 17(6): 566-72
79. Mattila C, Knekt P, Männistö S et al: Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care, 2007; 30(10): 2569-70
80. Pittas AG, Harris SS, Stark PC et al: The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care, 2007; 30(4): 980-86
81. Penckofer S, Kouba J, Wallis DE et al: Vitamin D and diabetes: let the sunshine in. Diabetes Educ, 2008; 34(6): 939-40, 942, 944 passim
82. Billaudel BJ, Delbancut AP, Sutter BC et al: Stimulatory effect of 1,25 dihydroxyvitamin D3 on calcium handling and insulin secretion by islets from vitamin D3-deficient rats. Steroids, 1993; 58(7): 335-41
83. Rojas-Rivera J, De La Piedra C, Ramos A et al: The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant, 2010; 25(9): 2850-65
84. Maestro B, Dávila N, Carranza MC et al: Identification of a Vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol, 2003; 84(2-3): 223-30
85. Maestro B, Molero S, Bajo S et al: Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3). Cell Biochem Funct, 2002; 20(3): 227-32
86. Hu P, Lu L, Hu B et al: Recapture of hepatic apolipoprotein B mRNA editing may be a promising strategy to relieve nephrotic dyslipidemia. Med Hypotheses, 2010; 75(6): 561-63
87. Hu P, Qin YH, Jing CX et al: Association of polymorphisms at restriction enzyme recognition sites of apolipoprotein B and E gene with dyslipidemia in children undergoing primary nephrotic syndrome. Mol Biol Rep, 2009; 36(5): 1015-21
88. Khajehdehi P: Effect of vitamins on the lipid profile of patients on regular hemodialysis. Scand J Urol Nephrol, 2000; 34(1): 62-66
89. Bonakdaran S, Ayatollahi H, Mojahedi MJ et al: Impact of treatment with oral calcitriol on glucose intolerance and dyslipidemia(s) in hemodialysis patients. Saudi J Kidney Dis Transpl, 2008; 19(6): 942-47
90. Gupta AK, Sexton RC, Rudney H: Effect of vitamin D3 derivatives on cholesterol synthesis and HMG-CoA reductase activity in cultured cells. J Lipid Res, 1989; 30(3): 379-86
91. Oh J, Weng S, Felton SK et al: 1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation, 2009; 120(8): 687-98
92. Rejnmark L, Vestergaard P, Heickendorff L et al: Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol, 2010; 2010: 957174
93. Auwerx J, Bouillon R, Kesteloot H: Relation between 25-hydroxyvitamin D3, apolipoprotein A-I, and high density lipoprotein cholesterol. Arterioscler Thromb, 1992; 12(6): 671-74
94. John WG, Noonan K, Mannan N et al: Hypovitaminosis D is associated with reductions in serum apolipoprotein A-I but not with fasting lipids in British Bangladeshis. Am J Clin Nutr, 2005; 82(3): 517-22
95. Dansky HM, Charlton SA, Barlow CB et al: Apo A-I inhibits foam cell formation in Apo E-deficient mice after monocyte adherence to endothelium. J Clin Invest, 1999; 104(1): 31-39
96. McNeish J, Aiello RJ, Guyot D et al: High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP binding cassette transporter-1. Proc Natl Acad Sci USA, 2000; 97(8): 4245-50
97. Adams MJ, Irish AB, Watts GF et al: Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. Thromb Res, 2008; 123(2): 374-80
98. Brophy DF, Martin RJ, Gehr TW et al: A hypothesis-generating study to evaluate platelet activity in diabetics with chronic kidney disease. Thromb J, 2005; 3(1): 3
99. Hewison M, Freeman L, Hughes SV et al: Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol, 2003; 170(11): 5382-90
100. Merke J, Milde P, Lewicka S et al: Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest, 1989; 83(6): 1903-15
101. Ohsawa M, Koyama T, Yamamoto K et al: 1alpha, 25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation, 2000; 102(23): 2867-72
102. Aihara K, Azuma H, Akaike M et al: Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem, 2004; 279(34): 35798-802
103. Jones G: Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha, 25-dihydroxyvitamin D(3). Semin Dial, 2007; 20(4): 316-24
104. Kunitomo M, Futagawa Y, Tanaka Y et al: Cholesterol reduces and corticosteroids enhance the toxicity of vitamin D in rats. Jpn J Pharmacol, 1989; 49(3): 381-88
105. Drüeke TB, Ritz E: Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol, 2009; 4(1): 234-41
106. Kuwabara A, Tsugawa N, Tanaka K et al: Improvement of vitamin D status in Japanese institutionalized elderly by supplementation with 800 IU of vitamin D(3). J Nutr Sci Vitaminol (Tokyo), 2009; 55(6): 453-58
107. Holick MF: Vitamin D deficiency. N Engl J Med, 2007; 357(3): 266-81